Skip to main content
SpringerLink
Log in

Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing’s disease

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Octreotide (OCT) is ineffective in patients with Cushing’s disease (CD) due to the cortisol-induced down-regulation of somatostatin receptor subtype 2 which was shown to be reversible in vitro by using anti-glucocorticoid mifepristone. This study aimed to verify, in vivo, if mifepristone can modulate response to acute OCT administration in patients with CD. Three men and two postmenopausal women (age 52.5 ± 2 years) with CD were enrolled in the study. OCT (100 μg, s.c.) was administered alone on the first day (OCT-only), and it was then given after mifepristone administration (2 × 200 mg, p.os, 12 and 1 h before OCT), 3 days later (OCT-mif). ACTH and cortisol levels were measured before OCT administration and every 60 min thereafter for 6 h. Baseline ACTH and cortisol values, nadir values and percentage decrements (Δn) were compared during both tests. Mean ACTH-Δn did not differ significantly during the two tests. Both tests induced a <30 % decrease in plasma ACTH in three patients (#1, 2 and 3) and a >50 % decrease in the other two cases (#4 and 5). Cortisol decreased in patients #4 and 5, during both tests. ACTH-Δn did not correlate with morning cortisol nor with urinary free cortisol values. Patients #4 and 5 with the highest ACTH-Δn had the lowest cortisol values after 1 mg of dexamethasone. Brief mifepristone pre-treatment does not modify ACTH and cortisol response to acute OCT administration in CD. However, OCT seems to be more effective in patients with partially preserved cortisol inhibitory feedback.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. J. Newell-Price, X. Bertagna, A.B. Grossman, L.K. Nieman, Cushing’s syndrome. Lancet 367, 1605–1617 (2006)

    Article  PubMed  CAS  Google Scholar 

  2. X. Bertagna, L. Guignat, Approach to the Cushing’s disease patient with persistent/recurrent hypercortisolism after pituitary surgery. J. Clin. Endocrinol. Metab. 98(4), 1307–1318 (2013)

    Article  PubMed  CAS  Google Scholar 

  3. S. Cannavo, B. Almoto, C. Dall’Asta, S. Corsello, R.M. Lovicu, E. De Menis, F. Trimarchi, B. Ambrosi, Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas. Eur. J. Endocrinol. 149(3), 195–200 (2003)

    Article  PubMed  CAS  Google Scholar 

  4. B.M. Biller, A.B. Grossman, P.M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A.R. Hermus, L.J. Hofland, A. Klibanski, A. Lacroix, J.R. Lindsay, J. Newell-Price, L.K. Nieman, S. Petersenn, N. Sonino, G.K. Stalla, B. Swearingen, M.L. Vance, J.A. Wass, M. Boscaro, Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 93(7), 2454–2462 (2008)

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. R. Pivonello, M.C. De Martino, P. Cappabianca, M. De Leo, A. Faggiano, G. Lombardi, L.J. Hofland, S.W. Lamberts, A. Colao, The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J. Clin. Endocrinol. Metab. 94(1), 223–230 (2009)

    Article  PubMed  CAS  Google Scholar 

  6. I. Shimon, L. Rot, E. Inbar, Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review. Pituitary 15(4), 608–613 (2012)

    Article  PubMed  CAS  Google Scholar 

  7. C. Beglinger, K. Hu, Y. Wang, E. Bouillaud, C. Darstein, Y. Wang, P. Mohideen, Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. Endocrine 42(2), 366–374 (2012)

    Article  PubMed  CAS  Google Scholar 

  8. A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, D. Mills, L.R. Salgado, B.M. Biller, A 12-month Phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med. 366(10), 914–924 (2012)

    Article  PubMed  CAS  Google Scholar 

  9. R.A. Feelders, W.W. de Herder, S.J. Neggers, A.J. van der Lely, L.J. Hofland, Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. Drugs Today (Barc.) 49(2), 89–103 (2013)

    CAS  Google Scholar 

  10. J. van der Hoek, S.W. Lamberts, L.J. Hofland, The role of somatostatin analogs in Cushing’s disease. Pituitary 7(4), 257–264 (2004)

    Article  PubMed  Google Scholar 

  11. L.J. Hofland, Somatostatin and somatostatin receptors in Cushing’s disease. Mol. Cell. Endocrinol. 286, 199–205 (2008)

    Article  PubMed  CAS  Google Scholar 

  12. A. Ben-Shlomo, H. Schmid, K. Wawrowsky, O. Pichurin, E. Hubina, V. Chesnokova, N.A. Liu, M. Culler, S. Melmed, Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J. Clin. Endocrinol. Metab. 94(11), 4342–4350 (2009)

    Article  PubMed  CAS  Google Scholar 

  13. F. Kelestimur, C. Utas, O. Ozbakir, A. Selçuklu, O. Kandemir, N. Ozcan, The effects of octreotide in a patient with Nelson’s syndrome. Postgrad. Med. J. 72(843), 53–54 (1996)

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. L.J. Hofland, S.W. Lamberts, R.A. Feelders, Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells. Neuroendocrinology 92(Suppl 1), 11–16 (2010)

    Article  PubMed  CAS  Google Scholar 

  15. Arregger, A.L., Cardoso, E.M., Sandoval, O.B., Monardes Tumilasci, E.G., Sanchez, R., Contreras, L.N.: Hormonal secretion and quality of life in Nelson syndrome and Cushing disease after long acting repeatable octreotide: a short series and update. Am. J. Ther. (2012) (Epub ahead of print)

  16. G.K. Stalla, S.J. Brockmeier, U. Renner, C. Newton, M. Buchfelder, J. Stalla, O.A. Muller, Octreotide exerts different effects in vivo and in vitro in Cushing’s disease. Eur. J. Endocrinol. 130, 125–131 (1994)

    Article  PubMed  CAS  Google Scholar 

  17. J. van der Hoek, M. Waaijers, P.M. van Koetsveld, D. Sprij-Mooij, R.A. Feelders, H.A. Schmid, P. Schoeffter, D. Hoyer, D. Cervia, J.E. Taylor, M.D. Culler, S.W. Lamberts, L.J. Hofland, Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am. J. Physiol. Endocrinol. Metab. 289, 278–287 (2005)

    Article  Google Scholar 

  18. C. de Bruin, R.A. Feelders, A.M. Waaijers, P.M. van Koetsveld, D.M. Sprij-Mooij, S.W. Lamberts, L.J. Hofland, Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids. J. Mol. Endocrinol. 42, 47–56 (2009)

    Article  PubMed  Google Scholar 

  19. F. Vignati, P. Loli, Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. J. Clin. Endocrinol. Metab. 81(8), 2885–2890 (1996)

    PubMed  CAS  Google Scholar 

  20. J.D. Carmichael, M. Fleseriu, Mifepristone: is there a place in the treatment of Cushing’s disease? Endocrine 44, 20–32 (2013)

    Article  PubMed  CAS  Google Scholar 

  21. G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88(12), 5593–5602 (2003)

    Article  PubMed  CAS  Google Scholar 

  22. A. Utz, B.M. Biller, The role of bilateral inferior petrosal sinus sampling in the diagnosis of Cushing’s syndrome. Arq. Bras. Endocrinol. Metabol. 51(8), 1329–1338 (2007)

    Article  PubMed  Google Scholar 

  23. L.K. Nieman, Update in the medical therapy of Cushing’s disease. Curr. Opin. Endocrinol. Diabetes Obes. 20(4), 330–334 (2013)

    PubMed  CAS  Google Scholar 

  24. T. Tateno, M. Kato, Y. Tani, K. Oyama, S. Yamada, Y. Hirata, Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr. J. 56(4), 579–584 (2009)

    Article  PubMed  CAS  Google Scholar 

  25. C. de Bruin, L.J. Hofland, L.K. Nieman, P.M. van Koetsveld, A.M. Waaijers, D.M. Sprij-Mooij, M. van Essen, S.W.J. Lamberts, W.W. de Herder, R.A. Feelders, Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing’s syndrome due to ectopic adrenocorticotropin secretion. J. Clin. Endocrinol. Metab. 97(2), 455–462 (2012)

    Article  PubMed  PubMed Central  Google Scholar 

  26. van der Pas, R., Feelders, R.A., Gatto, F., de Bruin, C., Pereira, A.M., van Koetsveld, P.M., Sprij-Mooij, D.M., Waaijers, A.M., Dogan, F., Schulz, S., Kros, J.M., Lamberts, S.W.J., Hofland, L.J.: Preoperative normalization of cortisol levels in Cushing’s disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists. J. Clin. Endocrinol. Metab. (2013) (Epub ahead of print)

  27. B. Ambrosi, D. Bochicchio, C. Fadin, P. Colombo, G. Faglia, Failure of somatostatin and octreotide to acutely affect the hypothalamic–pituitary–adrenal function in patients with corticotropin hypersecretion. J. Endocrinol. Invest. 13, 257–261 (1990)

    Article  PubMed  CAS  Google Scholar 

  28. N.J. Woodhouse, S. Dagogo-Jack, M. Ahmed, R. Judzewitsch, Acute and long-term effects of octreotide in patients with ACTH-dependent Cushing’s syndrome. Am. J. Med. 95(3), 305–308 (1993)

    Article  PubMed  CAS  Google Scholar 

  29. X. Bertagna, C. Bertagna, M.H. Laudat, J.M. Husson, F. Girard, J.P. Luton, Pituitary–adrenal response to the antiglucocorticoid action of RU 486 in Cushing’s syndrome. J. Clin. Endocrinol. Metab. 63(3), 639–643 (1986)

    Article  PubMed  CAS  Google Scholar 

  30. S. Johanssen, B. Allolio, Mifepristone (RU 486) in Cushing’s syndrome. Eur. J. Endocrinol. 157, 561–569 (2007)

    Article  PubMed  CAS  Google Scholar 

  31. F. Castinetti, M. Fassnacht, S. Johanssen, M. Terzolo, P. Bouchard, P. Chanson, C. Do Cao, I. Morange, A. Pico, S. Ouzounian, J. Young, S. Hahner, T. Brue, B. Allolio, B. Conte-Devolx, Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur. J. Endocrinol. 160, 1003–1010 (2009)

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Medicine, University of Messina, AOU Policlinico “G. Martino” (Pad. H, 4th Floor), Via Consolare Valeria 1, 98125, Messina, Italy

    Francesco Ferrau, Francesco Trimarchi & Salvatore Cannavo

Authors
  1. Francesco Ferrau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Trimarchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salvatore Cannavo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Ferrau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferrau, F., Trimarchi, F. & Cannavo, S. Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing’s disease. Endocrine 47, 550–556 (2014). https://doi.org/10.1007/s12020-013-0163-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-013-0163-0

Keywords

Search

Navigation